Viking Therapeutics Inc. (NASDAQ: VKTX) has taken investors on a wild ride since the beginning of 2024. At one point, VKTX stock was up 375% from its closing price on January 2, 2024. But it’s been a steady move lower. As of the market close on April 15, 2025, the stock is within 10% of that January 2024 close.
This week alone has been wild. Viking stock shot up approximately 12% on news that it was preparing to start a phase 3 study for its GLP-1 weight loss drug candidate, VK2735. However, the stock is struggling to hold those gains as investors got a reminder of the practical costs of these drugs that could hold back adoption.
